MEDI-528, now recognized as enokizumab , represents a novel therapeutic targeting the insulin-like growth factor 1 receptor , a key protein involved in multiple dermatological diseases . Early investigation https://joanbeyb854688.activoblog.com/51970022/enokizumab-a-deep-dive-into-medi-528-and-its-potential